Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CytRx, a biopharmaceutical research and development oncology company engaged in the development of human therapeutics, has received orphan drug status for tumor-targeting pro-drug candidate INNO-206 as the treatment for patients suffering with pancreatic cancer.
Subscribe to our email newsletter
INNO-206 is intended to control the release of chemotherapeutic doxorubicin and to preferentially target tumors, which the company believes may make it more effective and less toxic in cancer patients than doxorubicin.
INNO-206 demostrated positive results in animal trial with a human model of pancreatic cancer.
In the trial, INNO-206 showed three-fold reduction in the average primary tumor size, compared to the control.
Currently, CytRx is conducting a Phase 1b safety and dose escalation study with INNO-206 in patients with advanced solid tumors who have failed standard therapies and in the second half of this year, anticipates moving into Phase 2 clinical testing for patients suffering from soft tissue sarcoma.
CytRx president and CEO Steven Kriegsman said only a handful of drugs have shown any benefit for the treatment of patients suffering from progressing, cancer, and INNO-206 outperformed both doxorubicin and the current standard of care gemcitabine in the animal trial.
"We are now arranging advancement of INNO-206’s development for pancreatic cancer in a Phase 2 clinical trial," Kriegsman said.